Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

ANRO Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Alto Neuroscience, Inc.NYSE: ANRO

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$184K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$284K.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$184K or moves back toward the trailing-twelve-month quarterly average of -$71K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$184K— QoQ
Last fiscal yearDec 2025
-$661K-31.7% YoY
LTMMar 2026
-$284K-67.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-31.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(661K) USD
Year-over-year change
-31.7%

Gross Profit vs competitors

How ANRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -67.1% is the 4th highest of 6, against a peer median of -41.7%.
ANRO Competitors
Gross Profit for ANRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$112.77M USD+52.6%-20.7%52.5%
CLLSCellectis S.A.LTM Mar 2026$55.76M USD+43.8%+80.8%81.9%
ACIUAC Immune S.A.LTM Mar 2026CHF 3.7M CHF-86.9%-3.2%100.0%
KRROKorro Bio, Inc.LTM Mar 2026$2.81M USD-41.7%—73.2%
SLNSilence Therapeutics plcLTM Mar 2026$612.12K USD—-62.8%66.4%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$0 USD———
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$66.6K USD———
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$79K USD———
ANROAlto Neuroscience, Inc.LTM Mar 2026-$284K USD-67.1%——
DBVTDBV Technologies S.A.LTM Mar 2026-$17.4M USD-146.9%——
Peer median (excluding ANRO) —-41.7%-11.9%73.2%

Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue210K0000
Cost of Revenue145K342K0502K661K
Gross Profit65K(342K)0(502K)(661K)
Gross Margin31.0%————
Research & Development8.37M23.69M30.29M47M45.62M
Selling, General & Admin3.75M5.16M7.52M21.61M20.75M
Operating Expenses12.12M28.85M37.81M68.11M65.7M
Depreciation & Amortization145K342K373K502K661K
EBITDA(9.04M)(27.37M)(34.56M)(62.3M)(60.11M)
EBITDA Margin-4305.7%————
Operating Income(12.06M)(29.19M)(37.81M)(68.61M)(66.36M)
Operating Margin-5741.0%————
Interest Income2K114K2.35M8.85M6.6M
Interest Expense001.37M(1.38M)2.47M
Other Income / Expenses2.87M1.48M1.5M7.18M3.13M
Income Before Tax(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Pre-Tax Margin-4374.8%————
Income Tax Expense00000
Net Income(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Net Margin-4374.8%————
EPS (Basic)(0.36)(1.08)(1.35)(2.50)(2.19)
EPS (Diluted)(0.36)(1.08)(1.35)(2.50)(2.19)
Weighted Avg Shares25.57M25.57M26.88M24.6M28.85M
Weighted Avg Shares (Diluted)25.57M25.57M26.88M24.6M28.85M

Alto Neuroscience, Inc.

NYSE:ANRO

Intrinsic Alpha fair value

Locked

Current Price

$25.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.